The latest in drug and technology developments and updates from August 2026.

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

Optometrists should know what is expected, what is concerning, and when to contact the surgeon.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Host Hamza Shah, OD, MS, FAAO, is joined by Leonard Messner, OD, to discuss GLP-1s and idiopathic intracranial hypertension, inspired by Mitchell et al's paper, "The Effect of GLP-1RA Exenatide on Idiopathic Intracranial Hypertension: A Randomized Clinical Trial."

Catch up on the top stories in optometry during the week of August 24-28.

The agency assigned a PDUFA target action date of April 30, 2027.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.